Top Markets
Coin of the day
Apollo Endosurgery, Inc. Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc.

APEN
Rang in Aktien #18060
Apollo Endosurgery, Inc. is a medical technology firm specializing in the... Apollo Endosurgery, Inc. is a medical technology firm specializing in the creation, development, and commercialization of advanced medical instruments. Among its products are the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which empower physicians to perform advanced endoscopic procedures by suturing and securing tissue approximation via a flexible endoscope. The company also features the Orbera intragastric balloon system, available under brands such as Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System. This system aids in weight management by decreasing stomach capacity and slowing gastric emptying, thereby encouraging reduced food intake. Additionally, it provides the X-Tack Endoscopic HeliX Tacking System, a suture-based device designed for repairing defects in both the upper and lower gastrointestinal tract. Its medical solutions are distributed to various healthcare providers, including hospitals, outpatient surgical centers, clinics, and individual physicians, across the United States, Australia, Costa Rica, and several European nations. Founded in 2005, Apollo Endosurgery, Inc. maintains its headquarters in Austin, Texas.
Aktienkurs
$10.00
Zuletzt synchronisiert: 2023-04-11
Marktkapitalisierung
$214.01M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Apollo Endosurgery, Inc. (APEN)

Kategorie

EPS für Apollo Endosurgery, Inc. (APEN)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Apollo Endosurgery, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Apollo Endosurgery, Inc. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber